2-Methyl-5-[2]pyridylamino-phenol | 100142-25-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-Methyl-5-[2]pyridylamino-phenol
• 英文别名: 2-methyl-5-(pyridin-2-ylamino)phenol
• CAS: 100142-25-4
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: MJYSYVMJDSNKEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Methyl-5-[2]pyridylamino-phenol 、 1-溴-3-甲基-2-丁烯 在 caesium carbonate 作用下， 生成 N-(4-methyl-3-(3-methylbut-2-enyloxy)phenyl)pyridin-2-amine
  参考文献：
  名称：

  WO2007/38387

  摘要：

  公开号：
• 作为产物：
  描述：

  6-acetoxy-6-methylcyclohexa-2,4-dienone 在 2-氨基吡啶 作用下， 生成 2-Methyl-5-[2]pyridylamino-phenol
  参考文献：
  名称：

  Über die Umsetzung von o-Benzochinol-acetaten mit Aminen

  摘要：

  DOI：

  10.1007/bf00902387

文献信息

• Compounds and Methods for the Treatment of Viruses and Cancer
  申请人：Jorgensen William L.

  公开号：US20100222352A1

  公开（公告）日：2010-09-02

  The present invention relates to compounds according to the formula I: Where R a is H or an optionally OH-substituted C 1 -C 3 alkyl; R 1 is OR 1 , an optionally substituted C 4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R 1 is an optionally substituted C 1 -C 14 hydrocarbyl group or an optionally substituted heterocyclic group; R 2 , R 3 and R 4 are each independently H, an optionally substituted C 1 -C 4 alkyl group (preferably CH 3 , CH 2 CH 3 or CF 3 ), halogen (preferably F, Cl, Br), OR, CN, NO 2 , a C 1 -C 6 thioether, a C 1 -C 6 thioester group, an optionally substituted CO 2 R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R 4 is H); R is H or an optionally substituted C 1 -C 6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.

  本发明涉及公式I的化合物：其中R为H或可选择的OH取代的C1-C3烷基; R1为OR1，可选择取代的C4-12碳环基，可饱和或不饱和（包括芳香族）或可选择取代的杂环基; R1为可选择取代的C1-C14烃基或可选择取代的杂环基; R2、R3和R4各自独立地为H、可选择取代的C1-C4烷基（优选为CH3、CH2 或CF3）、卤素（优选为F、Cl、Br）、OR、CN、NO2、C1-C6硫醚、C1-C6硫酯基、可选择取代的CO2R基团、可选择取代的COR基团或可选择取代的OCOR基团（优选R4为H）; R为H或可选择取代的C1-C6烷基; RHET为可选择取代的杂环基;以及其药学上可接受的盐、溶剂或多晶体。
• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Kumar Naresh

  公开号：US20100222393A1

  公开（公告）日：2010-09-02

  Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R 1 and R 2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R 3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy; X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom; Het is heterocyclyl or heteroaryl; n is an integer from 1 to 6; are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and 4 i gastrointestinal systems mediated through muscarinic receptors.

  式(I)的化合物，其中当G为—OH时表示单键，当G为—O时表示双键；R1和R2分别选自氢、烷基、烯基、炔基、芳基烷基、环烷基、芳基、杂芳基、杂环烷基、杂环烷基烷基或杂芳基烷基；R3选自氢、羟基、烷氧基、烯氧基或炔氧基所选的群；X选自氧、—NH、—NR（其中R为烷基、烯基、炔基、芳基或烷基芳基）、硫或无原子；Het为杂环烷基或杂芳基；n为1至6的整数。这些化合物是肌肉性乙酰胆碱受体拮抗剂，可用于治疗通过肌肉性乙酰胆碱受体介导的呼吸系统、泌尿系统和胃肠系统的各种疾病，除其他用途外。
• Compounds and methods for the treatment of viruses and cancer
  申请人：Jorgensen William L.

  公开号：US09018209B2

  公开（公告）日：2015-04-28

  The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.

  本发明涉及化合物I式：其中Ra为H或有选择地取代的C1-C3烷基；R1为OR1，有选择地取代的C4-12碳环基，可以是饱和或不饱和的（包括芳香族）或有选择地取代的杂环基；R1为有选择地取代的C1-C14烃基或有选择地取代的杂环基；R2、R3和R4各自独立地为H，有选择地取代的C1-C4烷基（优选为CH3、CH2 或CF3）、卤素（优选为F、Cl、Br）、OR、CN、NO2、C1-C6硫醚、C1-C6硫酯基、有选择地取代的CO2R基、有选择地取代的COR基或有选择地取代的OCOR基（优选为R4为H）；R为H或有选择地取代的C1-C6烷基；RHET为有选择地取代的杂环基；以及其药学上可接受的盐、溶剂或多晶形式。
• Compositions of phosphodiesterase type IV inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2111861A1

  公开（公告）日：2009-10-28

  Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV ("PDE-IV"), and atleast one other active ingredients selected from muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, and corticosteroids and optionally one or more pharmaceutically acceptable excipients and/or other therapeutic agents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.

  本文提供的药物组合物包含一种或多种IV型磷酸二酯酶抑制剂（"PDE-IV"）、至少一种选自毒蕈碱受体拮抗剂（MRA）、β2-激动剂、p38 MAP激酶抑制剂和皮质类固醇的其他活性成分，以及可选的一种或多种药学上可接受的赋形剂和/或其他治疗剂。此外，还提供了治疗自身免疫性、炎症性或过敏性疾病或紊乱的方法。
• Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase
  作者：Juliana Ruiz-Caro、Aravind Basavapathruni、Joseph T. Kim、Christopher M. Bailey、Ligong Wang、Karen S. Anderson、Andrew D. Hamilton、William L. Jorgensen

  DOI：10.1016/j.bmcl.2005.10.037

  日期：2006.2

  Following computational analyses, potential non-nucleoside inhibitors of HIV-1 reverse transcriptase have been pursued through synthesis and assaying for anti-viral activity. The general class Het-NH-Ph-U has been considered, where Het is an aromatic heterocycle and U is an unsaturated, hydrophobic group. Results for compounds with Het = 2-thiazoyl and 2-pyrimidinyl are the focus of this report. (c) 2005 Elsevier Ltd. All rights reserved.